Radiesse Approved for Hand Treatment

 

Merz Aesthetics's Radiesse (calcium hydroxylapatite) has been approved by the U.S. Food and Drug Administration (FDA) for hand augmentation to correct volume loss in the dorsum of the hands. The long-term filler provides an immediate volumizing effect and can help to reduce the prominence of tendons and veins in the hands. It delivers smooth, natural-looking results that can last up to one year for more youthful-looking hands.

“Merz is proud to be able to provide patients and physicians with the first and only dermal filler approved by the FDA for use in the hands,” says Jim Hartman, vice president and head of U.S. Aesthetics/OTC for Merz North America. “Market research tells us that attention to the aesthetic appearance of hands has increased in recent years, particularly among individuals who have undergone facial rejuvenation procedures. This new indication for Radiesse is a result of our focus on meeting unmet needs in the U.S. aesthetics market, and we are excited to provide our physician customers with this new option.”

In a randomized, controlled U.S. trial, evaluators reported that Radiesse improved the appearance of both hands in 75 percent of treated patients at three months. Most adverse side effects were injection site reactions such as swelling, redness, pain, and bruising. These were usually mild to moderate, lasted only a week, and required no treatment.

Suggested Articles

Dermatologists are the leading influencers for cosmetic procedures and skincare choices.

Unrealistic expectations of self-image driven by social media lead to disappointed clients.

The FDA granted Erchonia 510(k) market clearance to market its EVRL for the temporary relief of chronic neck and shoulder pain.